Ranbaxy plunges to 3Q loss, remains silent on generic Lipitor plans
This article was originally published in Scrip
Executive Summary
There's still no official word on Ranbaxy Laboratories' launch plans for a generic version of Pfizer's money-spinning cholesterol drug Lipitor (atorvastatin) by the month end, even as the Indian firm, now part of Daiichi Sankyo, reported a loss of Rs4.65 billion ($93.9 million) for the third quarter ended 30 September compared with a profit of Rs3.1 billion in the year-ago quarter. Consolidated sales for the quarter, though, increased to $443 million as against $404 million in the same period of the previous year.